Blood Pressure
|
Pulse
|
Weight
|
Temperature
|
Glucose
|
Diagnosis
|
Medication
|
Sick Leave
|
Date
|
Actions |
NA
|
82
|
14.6
|
36.3
|
|
ECZEMA
|
MACROPEN S ALLERGEX S LENOVATE CRM
|
2021/03/07
|
0
|
Details
|
NA
|
55
|
15
|
36.5
|
|
URTI
|
AMYN TRIFEN PED SPAINBLOK SCEFTRXN INJ
|
2021/05/17
|
0
|
Details
|
NA
|
82
|
15.6
|
36,4
|
|
UTI
|
PURMYCIN S PAINBLOK S CEFTRXN INJ
|
2021/07/29
|
0
|
Details
|
NA
|
82
|
15.3
|
36.7
|
|
GE
|
AMYN PAINBLOKS CONTROMET S
|
2021/08/09
|
0
|
Details
|
NA
|
82
|
15.5
|
36.2
|
|
URTI
GE
|
MOXY TREIFEN PAINBLOK S CEFTRXN INJ
|
2021/10/28
|
0
|
Details
|
?
|
NA
|
16.2KG
|
37.0
|
|
URTI
|
ROCEPH STAT, MVT, CLEAR COUGH, PAINBLOCK, AMOXIL
|
2021/11/23
|
0
|
Details
|
NA
|
NA
|
17.2
|
36.2
|
|
URTI
|
AMOX SALTPYN TRIFEN
|
2022/05/16
|
0
|
Details
|
NA
|
82
|
17.7
|
37.5
|
|
URTI
|
AMYN TRIFEN PAINBLOMS
|
2022/05/31
|
0
|
Details
|
NA
|
82
|
19.1
|
36.6
|
|
urti
|
amyn bencough
|
2022/11/03
|
0
|
Details
|
NA
|
82
|
19.4
|
36.4
|
|
DERMATITIS
|
CEFTRXN INJ PAINBLOKS LENOVAT E CRM
|
2023/01/02
|
0
|
Details
|
N
|
N
|
22.1
|
36.3
|
|
CELLULTIS
|
AMYN PAINBLPKS
|
2023/08/03
|
0
|
Details
|
N
|
N
|
21.2
|
36.8
|
|
GE URTI
|
ROCIJEC TINJ PAINBLOKS PEKTIKON S CONTROMET
|
2023/08/21
|
0
|
Details
|
N
|
N
|
21.6
|
36.6
|
|
URTI
|
AMOX SALTPTYN ALCOP
|
2023/12/23
|
0
|
Details
|
N
|
N
|
22.4
|
36.4
|
|
URTI
|
AMYN TRIFEN TINEA CANEX INJ
|
2024/02/03
|
0
|
Details
|
N
|
N
|
24.0
|
36.3
|
|
CEFFRXN
|
AMYN LENOVATE CRM
|
2024/04/23
|
0
|
Details
|
N
|
N
|
22.7
|
37.3
|
|
URTI
|
CEFTRXN INJ PAINBLOKS TRIFEN
|
2024/05/07
|
0
|
Details
|
N
|
N
|
24.3kg
|
36.7
|
|
DERMATITIS
|
MACROPEN CANEX
|
2024/08/07
|
0
|
Details
|
N
|
N
|
24.0kg
|
36.7
|
|
MEASLES
|
CEFTRXN PURMYCIN PAINBKOIKS
|
2024/10/08
|
0
|
Details
|
|
|
23.8
|
36.5
|
|
|
|
2024/11/12
|
|
Details
|
NA
|
NA
|
25.4kg
|
36.5
|
|
URTI
|
FLU RX
|
2025/01/22
|
0
|
Details
|
n
|
n
|
25.0
|
36.7
|
|
urti tonsil
|
ceftrxn mamtyn trofen paijnbkok
|
2025/02/17
|
0
|
Details
|
N
|
N
|
N
|
N
|
|
URTI MOUTH SORES
|
CEFTRXN XERAMEL OAINBKOK
|
2025/04/04
|
0
|
Details
|